GlaxoSmithKline's China operation has been fined ¥3bn (£299m; €379m; $488m) after being found guilty of bribery by the Changsha Intermediate People's Court in Hunan province. In the closed door trial, which concluded on 19 September, five executives of GSK China Investment Company were also given suspended jail sentences of between two and four years.
The former manager, Mark Reilly, was given a four year suspended sentence and will be deported. The other four were Chinese nationals: the former human resources director, Zhang Guowei, former vice president, Liang Hong, former legal affairs director, Zhao Hongyan, and former business development manager, Huang Hong, each got suspended prison sentences of between two and four years for giving and receiving bribes.
In response to the sentences GSK published a statement of apology to the Chinese government and its people on its China website (www.gsk-china.com/english/index.asp) and announced that the costs to the company would be reflected in its third quarter update.
In a separate statement the company said that it had changed its incentive programme for sales staff in China, decoupling sales targets from compensation. It was also "significantly reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments."
GlaxoSmithKline's chief executive officer, Andrew Witty, said, "Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this. GSK has been in China for close to 100 years, and we remain fully committed to the country and its people."
The case came after the trial of the Shanghai based corporate investigator Peter Humphrey and his wife, Yu Yingzeng. GSK hired them to investigate the origin of claims by a company whistleblower of massive fraud.
1 2 The couple were charged with illegally obtaining private information and were detained in 2013. At a one day trial in Shanghai in August Humphrey was sentenced to two and a half years in prison, followed by deportation, and a fine of ¥200 000. Yu was jailed for two years and fined ¥150 000.
The punishment meted out to GSK and its employees has come as no surprise, said Leon Liu, a partner at the Shanghai law firm MWE China. "The monetary part of the judgment is a record but still within the anticipation of many people. The criminal part is showing the determination of the government, and the mercy is also there with all the suspended sentences."
The implications of the GSK and Humphreys case for other foreign players in the Chinese drug industry were clear, said Liu. "Foreign players will start to understand that the laws and regulations in China are not that different from their countries, and they need to include that into their global compliance policy," he said. "In the meantime, they also realise that in many ways China's legal practice is so different from what they are used to, like retaining a private investigator, even for an 'internal matter,'" he added.
